Navigation Links
Takeda San Francisco Enters Into A Sponsored Research Agreement With UCSF
Date:9/21/2009

SOUTH SAN FRANCISCO, Calif., Sept. 21 /PRNewswire/ -- Takeda San Francisco, Inc. (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced today that it has entered into a sponsored research collaboration with the University of California, San Francisco. The research program will focus on therapeutic antibody discovery and development to an undisclosed target. The agreement will solely support specific research conducted in the laboratory of Charles Craik, Ph.D., who will serve as the principal investigator for the project. This agreement enhances TSF's initiative to build a robust preclinical antibody therapeutics pipeline by leveraging the company's comprehensive and proprietary antibody technology platform and novel discovery, optimization and development technologies.

"This partnership is another example of UCSF's increasing commitment to using its world-class biomedical research programs to bring direct benefit to patients," said Dr. Regis Kelly, Executive Director of QB3, the California Institute for Quantitative Biosciences, one of four California Institutes for Science and Innovation.

"We're pleased to work with Dr. Craik, who is a leader in the field of proteases associated with disease pathogenesis," said Dr. Mary Haak-Frendscho, President and CSO of TSF. "We believe this research will help enable the discovery and development of a novel antibody product candidate to preclinical proof of concept. It furthermore demonstrates our commitment to working with academic experts concerning the development of novel biologic targets for the treatment of disease."

About Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody t
'/>"/>

SOURCE Takeda San Francisco, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
2. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
3. Chemizon Announces Research Collaboration Expansion With Takeda
4. Takeda submits new drug application for alogliptin (syr-322) in the US
5. Takeda Announces New U.S. Leadership
6. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. Takeda Completes Acquisition of Millennium
9. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
10. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
11. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 The American Telemedicine Association ... Thad Cochran (R-MS) and Roger Wicker (R-MS) for ... coverage under Medicare, Medicaid and Federal Communications Commission ... Republicans, introduced the Telehealth Enhancement Act as S. ... H.R. 3306, introduced by Rep. Gregg Harper (R-MS) ...
(Date:7/30/2014)... July 30, 2014 2014 ... Chitosan Industry” is a professional and in-depth ... The report provides basic Chitosan information, including ... structure as well as industry overview. This ... domestic market as well as global industry ...
(Date:7/30/2014)... 2014 (HealthDay News) --,Although the vast majority of kids ... still wired very differently from children who have trouble ... processing disorders (SPD) can be overly sensitive to sound, ... skills and show a lack of concentration. Complicating ... than others. Some have trouble tolerating loud noises, like ...
(Date:7/30/2014)... Everyone knows that the internet is the ... people are looking for something to buy, trying to reconnect ... internet is pretty much always going to be the go ... Florida is so happy to announce the launch of their ... the modern age. Whether a person wants to know what ...
(Date:7/30/2014)... With the recent May 21st opening of ... Zero Museum Workshop in the Meatpacking District has been encountering ... Workshop's Carole Barnes, "We have had to re-write the description ... sites who sell us so tourists don't confuse the two ... what we do and what the new Museum does in ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5
... Featured Panelist ... PHILADELPHIA, Sept. 16 Stop Falls Now! That is not just,a ... 2008,Annual Meeting and Exposition, but is now a reality. For the ... at this show., Beyond slogans or theory, LTC providers will ...
... Sept. 16 The National,Autism Association announced ... the first recipients of Project Lifesaver funding ... to counter the rise in,wandering-related deaths among ... a nationwide tracking program established to,quickly locate ...
... improved motor functioning, study finds , , TUESDAY, Sept. ... HDACi 4b reversed Huntington,s disease symptoms in mice ... at the Scripps Research Institute in California. ... affects people,s movement and thinking ability. There is ...
... Coalition Launched to Lobby for Improved Nurse Staffing in ... announced his support for state legislation that would increase ... Speaking at a press,conference called by the RN2RN Network, ... to take action to protect patients., "Given estimates ...
... Pa., Sept. 16 Particle Sciences, Inc.,announces the ... system for,increasing the density of sintered metal products. ... in a way that decreases needed,injection forces, decreases ... is based on a proprietary coating,applied to the ...
... percent increase in the number of air ambulance flights they operated ... ... AZ (PRWEB) September 16, 2008 -- Angel MedFlight Worldwide www.angelmedflight.com ... number of air ambulance flights they operated in the second quarter ...
Cached Medicine News:Health News:Samarion(SM) to Demonstrate Unprecedented Fall Prevention Component of Enterprise Quality Improvement System for LTC Facilities at the AAHSA 2008 Annual Meeting & Exposition 2Health News:National Autism Association's 'FOUND' Provides Funds to Union County Sheriff's Office for Project Lifesaver Equipment 2Health News:Compound Reverses Huntington's Symptoms in Mice 2Health News:Lt. Gov. Quinn Backs Patient Care Reforms 2Health News:Lt. Gov. Quinn Backs Patient Care Reforms 3Health News:Particle Sciences Develops Methods for Increasing Quality of Sintered Metal Products and for Coating Surfaces with Metal Oxide Films 2Health News:Substantial Second Quarter Surge for Angel MedFlight Worldwide Air Ambulance Services 2
(Date:7/30/2014)... 30, 2014   Unique Pizza and Subs ... Pink: UPZS), a Delaware Corporation, is pleased to ... Larasan Pharmaceutical Corporation ("Larasan"), a nature-based pharmaceutical company that ... agreement, US-based Larasan will work with Unique to ... through Larasan,s vast distribution network throughout ...
(Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
(Date:7/30/2014)... N.Y. and PARIS , ... REGN ) and Sanofi (EURONEXT: SAN and NYSE: ... Phase 3 ODYSSEY trials of alirocumab in people with ... percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) ...  Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... N.C., Aug. 12, 2011 Although medical devices ... complexities require medical device companies to invest more ... generic pharmaceutical products.   Tactical marketers ... activities, such as troubleshooting post-launch and managing product ...
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical and medical applications, has entered into ... Solutions Australasia Pty. Ltd., based in Newport, Victoria, ...
Cached Medicine Technology:Medical Device Marketing Groups Focus More Resources on Tactical Activities When Compared to Pharmaceutical Counterparts 2Misonix Announces New Distribution Agreement for Australia and New Zealand 2Misonix Announces New Distribution Agreement for Australia and New Zealand 3
... High Productivity, improved safety and lower cost per ... solution to sample prep bottlenecks in the busy ... amazingly compact and quiet centrifuge spins standard 5 ... yet it produces quality serum or plasma equal ...
The StatSpin Express 3 provides faster turnaround time and greater productivity for your laboratory....
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: